Amacathera is a company that brings together commercial leaders, researchers, and biotechnology experts to develop therapeutics aimed at improving patient outcomes.

Amacathera

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals.

We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. 

Currently, we have developed a combination product for post-operative pain, which is our company's lead project.

Johnson & Johnson Robotics and Digital Solutions

Viva BioInnovator

BDC Capital’s Women in Technology Venture Fund

CR Capital Management

Sprout BioVentures

StandUp Ventures

Lumira Ventures

MaRS Investment Accelerator Fund

MBX Capital

Inveready

AmacaThera

AmacaThera Updates - August 2024

Our Business Development Lead Darren Rodenhizer, PhD has prepared an update on our clinical and business development achievements so far in 2024, with an eye toward our strategy for 2025.

We have also launched a quarterly newsletter that will provide regular updates like this on our progress - you can sign up for the newsletter by visiting our website: www.amacathera.ca

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

Read the press release here:

https://lnkd.in/e2eaExBX

Congratulations to our Co-Founder and CSO, Molly Shoichet on being named the inaugural Pamela and Paul Austin Chair in Precision and Regenerative Medicine at the University of Toronto!

#precisionmedicine
#regenerativemedicine
#toronto

Congratulations to our Co-Founder and Chief Science Officer Molly Shoichet and team on launching BioNetHub -- $19M in funding to address the HQP shortage in #biomanufacturing.

Great presentation by Darren at Pharma Partnering Summit, San Diego

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 24, 2024 2:24 PM	e387db3d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 11, 2024 10:30 AM	c2bf34c0
crunchbase profile	general
li profile	general	Aug 24, 2024 2:24 PM	269aab95
translate crunchbase fundingrounds	general
peers	general	Aug 24, 2024 2:24 PM	c67ad598
news basic	general	Aug 24, 2024 2:24 PM	325f3a0c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

AMAC

CA:AMACATHERA

Amacathera